title: Fluvastatin combined with benazepril may contribute to the favorable prognosis of patients with atrial fibrillation.
abstract: The aim of this study was to observe the clinical efficacy of fluvastatin combined with benazepril in the treatment of patients with atrial fibrillation (AF). A total of 92 patients with AF were randomly assigned to the case group (n=46), in which the patients were treated with fluvastatin (80mg) plus benazepril (10mg), or to the control group (n=46), in which the patients were treated with fluvastatin (80mg). The conversion rate of sinus rhythm was higher in the case group than in the control group (P<0.05). The case group had more treatment-effective patients than the control group, with fewer treatment-ineffective patients (P<0.05). The LVEDd, LVESd, LAD, and LVEF indexes in the case group were lower than in the control group after 6 months of treatment (all P<0.05). Levels of hs-CRP were also lower in patients in the case group than in patients in the control group after 1 month of treatment (P<0.05). After 12 months, renin and Ang II concentrations were lower in patients in the case group than in the control group (both P<0.05). Significant differences in IL-6 and TNF-α expression were found between the two groups after 1 month, 6 months, and 12 months of treatment (all P<0.05). Compared to patients in the control group, the levels of total cholesterol (TC), triglycerides, and LDL-C in the case group were lower after 6 and 12 months of treatment (all P<0.05), while the HDL level was higher (P<0.05). Treatment with fluvastatin combined with benazepril further increased the conversion rate of sinus rhythm and significantly improved the quality of life and prognosis of AF patients.
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150086, PR China.
authors.forename: Hong
authors.initials: H
authors.lastname: Yao
authors.affiliation: Department of Hematology, Harbin Medical University Cancer Hospital, Harbin 150086, PR China.
authors.forename: Li
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150086, PR China.
authors.forename: Xi
authors.initials: X
authors.lastname: Lin
authors.affiliation: Department of Cardiology, The First Affiliated Hospital of Harbin Medical University, Harbin 150086, PR China. Electronic address: liangzhaoguang_ab@163.com.
authors.forename: Zhao-Guang
authors.initials: ZG
authors.lastname: Liang
mesh_terms: D000804:Angiotensin II / Q000097:blood; D001281:Atrial Fibrillation / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000378:metabolism; D016022:Case-Control Studies; D004359:Drug Therapy, Combination; D005229:Fatty Acids, Monounsaturated / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D000077340:Fluvastatin; D006334:Heart Function Tests; D006801:Humans; D007211:Indoles / Q000494:pharmacology / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000097:blood; D007668:Kidney / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008099:Liver / Q000187:drug effects / Q000473:pathology / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012083:Renin / Q000097:blood; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D001552:Benzazepines; D005229:Fatty Acids, Monounsaturated; D007211:Indoles; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000804:Angiotensin II; D000077340:Fluvastatin; D002097:C-Reactive Protein; D012083:Renin; C044946:benazepril
keywords: Ang II; Atrial fibrillation; Benazepril; Fluvastatin; IL-6; Renin; Sinus rhythm conversion rate; TNF-α; hs-CRP